Login to Your Account



FDA Dings Takeda/Furiex Type II Diabetes Duo

By Catherine Shaffer
Staff Writer

Friday, April 27, 2012
The FDA issued a complete response letter to Takeda Pharmaceutical Co. Ltd. regarding new drug applications for alogliptin and fixed-dose combinations of alogliptin and pioglitazone for Type II diabetes, products partnered with Furiex Pharmaceuticals Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription